UY29740A1 - Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol - Google Patents

Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol

Info

Publication number
UY29740A1
UY29740A1 UY29740A UY29740A UY29740A1 UY 29740 A1 UY29740 A1 UY 29740A1 UY 29740 A UY29740 A UY 29740A UY 29740 A UY29740 A UY 29740A UY 29740 A1 UY29740 A1 UY 29740A1
Authority
UY
Uruguay
Prior art keywords
salbutamol
formulations
hfc
citrate
hydrochloride
Prior art date
Application number
UY29740A
Other languages
English (en)
Inventor
Friedrich Schmidt
Mariela Mann
Michael Cope
Hlger Mmmesheimer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY29740A1 publication Critical patent/UY29740A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulaciones de disolución para aerolol estabilizadas que contienen sales de edicinon de ácido de salbutamol, adecuadas para sua administración poe inhaladores de dosis medidas (los MDI).Formulaciones de una disolición que contiene un a de la sales mencionadas anteriormente de salburamol, preferiblemente hidroclururo de dalbutamolo citrato de salbutamol, más preferiblemente una de dicha sales en combinación con una o más sustancias farmacológicamente activas adicionales, junto con un hidrofluorocabono (HFC) medioambientalmente seguro como propelente, un disolvente conjunto, preferiblemente un compuesto orgánico como disolvente conjunto y bién un ácido inorgánico o un ácido orgánoco.
UY29740A 2005-08-12 2006-08-11 Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol UY29740A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017599 2005-08-12

Publications (1)

Publication Number Publication Date
UY29740A1 true UY29740A1 (es) 2007-03-30

Family

ID=35564491

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29740A UY29740A1 (es) 2005-08-12 2006-08-11 Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol

Country Status (6)

Country Link
US (1) US20070041911A1 (es)
AR (1) AR057745A1 (es)
PE (1) PE20070353A1 (es)
TW (1) TW200800141A (es)
UY (1) UY29740A1 (es)
WO (1) WO2007020204A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
WO2017093758A1 (en) 2015-12-04 2017-06-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
ES2877575T3 (es) 2016-09-19 2021-11-17 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende salmeterol
EP3610871B1 (en) 2016-09-19 2023-11-08 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
FR3130554A1 (fr) * 2021-12-20 2023-06-23 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
CA2111003A1 (en) * 1991-06-10 1992-12-23 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
JP2003221335A (ja) * 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
CN1216600C (zh) * 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
CN1228045C (zh) * 2003-11-03 2005-11-23 王立强 口腔速崩速溶片制剂及其制备方法
GB0406069D0 (en) * 2004-03-17 2004-04-21 Thompson James Process

Also Published As

Publication number Publication date
PE20070353A1 (es) 2007-04-19
TW200800141A (en) 2008-01-01
US20070041911A1 (en) 2007-02-22
WO2007020204A2 (en) 2007-02-22
WO2007020204A3 (en) 2007-06-07
AR057745A1 (es) 2007-12-12

Similar Documents

Publication Publication Date Title
UY29740A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
ECSP045238A (es) Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente
ATE341309T1 (de) Pulmonale arzneistoffverabreichung
UY30265A1 (es) Inhalador
ECSP088653A (es) Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva
ECSP077368A (es) Mecanismo de visualización de dosis para un dispositivo para la administración de fármacos
AR057180A1 (es) Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion
WO2006044421A3 (en) Cardiac safe, rapid medication delivery
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
CO6382132A2 (es) Tratamiento de pirfenidona para pacientes con funcion hepatica atipica
BRPI0507225A2 (pt) formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
AR059359A1 (es) Formulaciones farmaceuticas que contienen pleconaril
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
CO6321158A2 (es) Formulacion oral
NO20082097L (no) Farmasoytiske sammensetninger
DK2089008T3 (da) Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator
NO20074854L (no) Farmasoytiske aerosolformuleringer for komprimerte, utmalte doseinhalatorer omfattende et sekvestreringsmiddel
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
BRPI0417350A2 (pt) composiÇço para a distribuiÇço nasal, uso de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e quitosana, um sal, um derivado ou sal de um derivado do mesmo, mÉtodos de administraÇço de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e de tratamento ou prevenÇço de nÁusea e/ou vâmito, e, dispositivo para a distribuiÇço da droga nasal ou um cartucho de dose
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
WO2005097192A3 (en) Active substance combination of a carbinol compound and an opioid

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160830